SLVM — Sylvamo Corp · 2026-09-05 · Verdict: WATCH · Conviction 2

Price $35.53 (screen row, 2026-09-04; no live prices available) · Mkt cap $1.41B (39.76M sh) · EV $2.25B (corrected) · EV/2025 segment EBIT 9.0x · EV/LTM adj. EBITDA 6.2x · LTM FCF yield negative · Net debt $841M · ADV $9.6M Sources read: 10-K filed 2026-02-20 (Items 1, 1A, 7), 10-Q filed 2026-08-07, DEF 14A filed 2026-04-02, 8-Ks 2026-05-08 and 2026-08-07 (EX-99.1 releases), Form 4s (12 of 90 filed in trailing 12m). No transcript in the bundle.

1. What the business actually does

Sylvamo makes uncoated freesheet paper (copy, offset, converting) and market pulp at mills in Europe (Saillat, France and Nymolla, Sweden), Latin America (three Brazilian mills plus roughly 250,000 acres of eucalyptus forestland) and North America (Eastover, South Carolina and Ticonderoga, New York), under brands including Hammermill, Chamex, REY and Multicopy. It was spun out of International Paper in 2021. Its North and Latin American mills sit predominantly in the lowest quartile of the global UFS cost curve, and the four largest North American producers hold about 80% of capacity (10-K 2025, Item 1). The top ten customers are roughly 41% of net sales and one is about 15% (10-K 2025, Item 1A).

2. Why it is mispriced — the edge case

There is no forced seller I can identify from the filings, and that is the honest answer. The one candidate is the Atlas Group, which beneficially owned about 16% of the shares as of the 2026 record date; its two board designees resigned on November 5, 2025, most Cooperation Agreement obligations terminated on November 13, 2025, and Sylvamo had to keep a shelf registration effective to let Atlas sell until August 13, 2026 (DEF 14A 2026). Nothing in the bundle shows Atlas sold, so I will not underwrite it.

What is real is an optical distortion. The screen reads 8.5x EV/EBIT off CY2025 numbers and calls Sylvamo a buyback story at -1.5% shares; both are stale, no shares were repurchased in the first half of 2026, and the screen omitted $121M of notes payable and current maturities, so true enterprise value is $2.25B, not $2.13B (10-Q Q2 2026). Meanwhile 2026 GAAP looks awful for reasons management dates and sizes: the Riverdale offtake agreement with International Paper terminated at the end of April 2026 and Eastover takes an extended fourth-quarter outage, together an unfavorable $85M hit to full-year 2026 Adjusted EBITDA (10-Q Q2 2026, MD&A). Screens see a cash-burning paper company; the filings describe a dated, self-inflicted transition. That gap is genuine but is spelled out in a widely read filing, which is why I do not count it as an edge.

3. Unit economics and growth

2025 net sales were $3,351M against $3,773M in 2024, net income $132M against $302M, and Adjusted EBITDA $448M (13% margin) against $632M (17%); segment operating profit fell to $251M from $453M, with Europe swinging to a $112M loss from $10M of profit on price and mix ($73M) and outages ($39M) (10-K 2025, Item 7). First-half 2026 is worse: sales $1,561M, a $14M net loss, Adjusted EBITDA $89M against $172M, free cash flow negative $82M against negative $27M, and Q2 segment losses of $20M in Europe and $16M in Latin America (10-Q Q2 2026; 8-K 2026-08-07).

Pricing power exists but is thin. Price increases went in across all three regions in the first half with realization expected through Q3, and Riverdale's conversion removed roughly 7% of annual North American UFS supply, but Q2 imports rose on the 10% tariff window (8-K 2026-08-07) and first-half price and mix was still negative $37M (10-Q Q2 2026). Underneath it all the company reports global UFS demand falling at a 2.1% CAGR from 2019 to 2025 and 1.1% from 2021 to 2025 on RISI data (10-K 2025, Item 1A). Returns were once excellent and are not now: LTIP ROIC was 21.3% in 2023, 23.2% in 2024 and 11.7% in 2025 (DEF 14A 2026).

4. Balance sheet and capital allocation

At June 30, 2026 cash was $123M against $121M of current debt and $843M of long-term debt, so net debt is $841M, 2.3x LTM Adjusted EBITDA of $365M and about 3.0x my 2026 estimate; equity is $955M. In the first half the company settled the $257M Term Loan F with a new $357M Term Loan F-3 and drew $178M on the revolver; net debt rose while $36M of dividends were paid and no stock was bought back, so the $1.80 annual dividend is currently funded with borrowings (10-Q Q2 2026). Free cash flow ran $269M, $294M, $248M and $44M across 2022 to 2025 (DEF 14A 2026), and $150M of the $450M buyback authorization remains. A covenant tied to the unresolved Brazil goodwill-amortization dispute (about $106M of tax plus $289M of interest and penalties, shared with International Paper) can restrict dividends and repurchases after an adverse ruling if liquidity tests are missed or $60M is not escrowed (10-K 2025, Item 1A). Pay is honestly calibrated: the 2023 LTIP paid 0% on ROIC and the outgoing CEO's annual incentive fell to $395,100 in 2025 from $2,163,800 in 2024 (DEF 14A 2026). Of the 12 Form 4s the pack captured, every transaction was a grant, dividend-equivalent accrual or tax withholding, with no open-market purchase.

5. Management: what they said versus what they did

Jean-Michel Ribieras left as CEO on December 31, 2025, John Sims became CEO on January 1, 2026 and Donald Devlin became CFO on May 1, 2025 (DEF 14A 2026), so both signatures on the recovery plan are new. In May, Sims said tariff-driven replanning would cut 2026 transition costs by about $20M (8-K 2026-05-08); by August the transition was still sized at $85M for the year (10-Q Q2 2026). He said in both quarters that free cash flow is heavily weighted to the second half, which is verifiable in February. The standing aspiration of over $300M of annual free cash flow and over 15% ROIC (8-K 2026-08-07) is explicitly conditioned on "as industry conditions turn," and 2025 delivered $44M and 11.7%. It is a cycle-peak marker, not guidance.

6. Valuation

Base (50%): 2026 Adjusted EBITDA near $280M (first half $89M plus a second half helped by price realization and Latin American seasonality but carrying the Nymolla and Eastover fourth-quarter outages), then about $400M in 2027 as the $85M transition does not repeat and Eastover adds the guided $30M to $40M (10-Q Q2 2026); at 5.5x on $850M of net debt, roughly $34. Bear (25%): the cycle does not turn, 2027 Adjusted EBITDA near $300M at 5.0x with net debt at $950M, about $14. Bull (25%): European losses reverse and price sticks, 2027 Adjusted EBITDA of $500M (still below 2024's $632M) at 6.0x with net debt at $750M, about $57. Weighted, roughly $34.75, about 2% below the $35.53 screen price. Reverse DCF: at $35.53 enterprise value is $2.25B, so at a 10% discount rate with a 2% perpetual decline matching the company's own reported UFS demand CAGR, the price implies about $270M of unlevered free cash flow every year forever, against roughly $140M implied by the 2027 base case and about $283M actually produced in the 2024 peak year.

7. Catalysts and timeline

Q3 results in early November, the first quarter with full price realization and no Riverdale drag. Completion of the Eastover paper machine optimization in the planned fourth-quarter outage, adding 60,000 short tons from early 2027. Softwood woodyard startup and the sheeting warehouse sale-leaseback, both first quarter 2027. Full-year results and 2027 outlook in February 2027. Brazil tax rulings, timing unknown.

8. Risks and pre-registered kill criteria

Risks: company-admitted secular decline, commodity pricing it cannot time, one customer at 15% of sales, energy and freight inflation from the Middle East conflict, and a Brazil tax exposure whose interest and penalties alone exceed a fifth of the market cap. 1. Full-year 2026 Adjusted EBITDA below $260M when reported in February 2027. 2. Net debt above $950M at any quarter end while the dividend is maintained. 3. The Eastover paper machine optimization slips past the fourth-quarter 2026 outage, or the 2027 benefit is guided below $30M. 4. The dividend is cut or suspended, or restricted-payment covenant limits are triggered by an adverse Brazil ruling.

9. Verdict and one-paragraph summary

WATCH, conviction 2. Sylvamo is a genuine low-cost paper producer at a genuine trough, and the 2026 wreckage is dated and sized by the company itself, an $85M hit from the Riverdale exit and the extended Eastover outage that should not repeat plus $30M to $40M of new Eastover benefit in 2027, but nothing here is mispriced enough to act on. The screen's 8.5x is stale CY2025 arithmetic that also missed $121M of current debt, so real enterprise value is $2.25B and 6.2x LTM Adjusted EBITDA of $365M, with trailing free cash flow negative and net debt of $841M rising while the $1.80 dividend is funded by borrowings. The stock is only 34% off its 52-week high with no identifiable forced seller, no open-market insider buying in the Form 4s the pack captured, and a business the company's own risk factors describe as in secular decline at a 1.1% to 2.1% CAGR. Probability-weighted value of about $34.75 is 2% below the price, and the reverse DCF says the price already embeds a permanent return to 2024 free cash flow, so what to wait for is Q3 and Q4 evidence that price increases stuck and second-half cash arrived.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.